{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:41:27Z","timestamp":1792633287552,"version":"4.5.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Studies to evaluate markers of thrombotic risk in individuals with high-risk membranous nephropathy (MN) are needed. We hypothesized that high anti-phospholipase A2 receptor (PLA2R) titers at the time of severe hypoalbuminemia, reflecting ongoing immunologic disease activity, may be associated with a higher risk of thrombotic complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a multicenter retrospective cohort study of individuals with membranous nephropathy and serum albumin &amp;lt;2.5\u2005g\/dL and evaluated risk factors for first thrombotic events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixty-seven individuals met the inclusion criteria. Median serum creatinine was 1.2\u2005mg\/dL (Interquartile range [IQR] 0.9\u20131.6), median urine protein-to-creatinine ratio (UPCR) was 11.9\u2005g\/g (IQR 8.5\u201316.5), and median nadir serum albumin level was 1.9\u2005g\/dL (IQR 1.6\u20132.2). Twenty-four individuals (36%) received no thromboprophylaxis, 20 (30%) received prophylaxis with only antiplatelets, and 23 (34%) received anticoagulation prophylaxis. Thrombotic events occurred in 11 individuals (16%) with incidence rates of 0.11, 0.10, and 0.02 per person-year in the no prophylaxis, antiplatelet, and anticoagulation groups, respectively. In individuals with anti-PLA2R antibody-positive MN who did not receive anticoagulation thromboprophylaxis, higher anti-PLA2R antibody levels were associated with a higher risk of developing thrombotic complications (adjusted Hazard Ratio [HR] = 1.51 per 10 RU\/mL increase in PLA2R, 95% Confidence Interval [CI]: 1.10\u20132.09, P = .012) after adjusting for serum albumin nadir and age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Higher anti-PLA2R antibody levels at the time of hypoalbuminemia are associated with a higher risk of thrombotic complications in individuals with anti-PLA2R-positive MN.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/joneph\/aajag121","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T11:30:22Z","timestamp":1777289422000},"page":"1411-1419","source":"Crossref","is-referenced-by-count":0,"title":["Anti-PLA2R antibody levels are associated with thromboembolism risk in individuals with membranous nephropathy and hypoalbuminemia"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7652-3399","authenticated-orcid":false,"given":"Ayman","family":"Al Jurdi","sequence":"first","affiliation":[{"name":"Division of Nephrology, Massachusetts General Hospital , Boston, MA ,","place":["United States"]},{"name":"Vasculitis and Glomerulonephritis Center, Massachusetts General Hospital; Boston , MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"El Mouhayyar","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Massachusetts General Hospital , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Yatim","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Massachusetts General Hospital , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4852-9061","authenticated-orcid":false,"given":"Orhan","family":"Efe","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Massachusetts General Hospital , Boston, MA ,","place":["United States"]},{"name":"Vasculitis and Glomerulonephritis Center, Massachusetts General Hospital; Boston , MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saif A","family":"Muhsin","sequence":"additional","affiliation":[{"name":"Division of Renal Medicine, Brigham and Women's Hospital, Harvard Medical School , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo V","family":"Riella","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Massachusetts General Hospital , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7389-4549","authenticated-orcid":false,"given":"Reza","family":"Zonozi","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Massachusetts General Hospital , Boston, MA ,","place":["United States"]},{"name":"Vasculitis and Glomerulonephritis Center, Massachusetts General Hospital; Boston , MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Laliberte","sequence":"additional","affiliation":[{"name":"Vasculitis and Glomerulonephritis Center, Massachusetts General Hospital; Boston , MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L","family":"Niles","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Massachusetts General Hospital , Boston, MA ,","place":["United States"]},{"name":"Vasculitis and Glomerulonephritis Center, Massachusetts General Hospital; Boston , MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushya","family":"Jeyabalan","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Massachusetts General Hospital , Boston, MA ,","place":["United States"]},{"name":"Vasculitis and Glomerulonephritis Center, Massachusetts General Hospital; Boston , MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"2026102121370782500_aajag121-B1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med."},{"key":"2026102121370782500_aajag121-B2","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/ki.2011.312","article-title":"Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis","volume":"81","author":"Barbour","year":"2012","journal-title":"Kidney Int."},{"key":"2026102121370782500_aajag121-B3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2215\/CJN.04250511","article-title":"Venous thromboembolism in patients with membranous nephropathy","volume":"7","author":"Lionaki","year":"2012","journal-title":"Clin J Am Soc Nephrol."},{"key":"2026102121370782500_aajag121-B4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000188355","article-title":"Prevention of thrombotic complications of the nephrotic syndrome by the low-molecular-weight heparin enoxaparin","volume":"69","author":"Rostoker","year":"1995","journal-title":"Nephron"},{"key":"2026102121370782500_aajag121-B5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12882-019-1336-8","article-title":"Prophylactic anticoagulation in nephrotic syndrome prevents thromboembolic complications","volume":"20","author":"Kelddal","year":"2019","journal-title":"BMC Nephrol."},{"key":"2026102121370782500_aajag121-B6","doi-asserted-by":"publisher","first-page":"478","DOI":"10.2215\/CJN.07190713","article-title":"Retrospective analysis of a novel regimen for the prevention of venous thromboembolism in nephrotic syndrome","volume":"9","author":"Medjeral-Thomas","year":"2014","journal-title":"Clin J Am Soc Nephrol."},{"key":"2026102121370782500_aajag121-B7","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.1055\/a-1920-6224","article-title":"Apixaban prophylactic anticoagulation in patients with nephrotic syndrome","volume":"6","author":"Van Meerhaeghe","year":"2022","journal-title":"TH Open"},{"key":"2026102121370782500_aajag121-B8","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s12882-022-02929-x","article-title":"Safety and effectiveness of direct oral anticoagulants in patients with nephrotic syndrome: a report of 21 cases","volume":"23","author":"Kelddal","year":"2022","journal-title":"BMC Nephrol."},{"key":"2026102121370782500_aajag121-B9","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3892\/etm.2017.5471","article-title":"Rivaroxaban for the treatment of venous thromboembolism in patients with nephrotic syndrome and low AT-III: a pilot study","volume":"15","author":"Zhang","year":"2018","journal-title":"Exp Ther Med."},{"key":"2026102121370782500_aajag121-B10","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1080\/0886022X.2019.1635030","article-title":"The role of prophylactic use of low molecular weight heparin or aspirin in thromboembolic events in primary membranous nephropathy","volume":"41","author":"Zou","year":"2019","journal-title":"Ren Fail."},{"key":"2026102121370782500_aajag121-B11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s13318-011-0037-x","article-title":"Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor","volume":"36","author":"He","year":"2011","journal-title":"Eur J Drug Metab Pharmacokinet."},{"key":"2026102121370782500_aajag121-B12","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1177\/0091270006292127","article-title":"Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban-an oral, direct factor Xa inhibitor-are not affected by aspirin","volume":"46","author":"Kubitza","year":"2006","journal-title":"J Clin Pharmacol."},{"key":"2026102121370782500_aajag121-B13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/ndt\/gfw227","article-title":"Association of serum albumin level and venous thromboembolic events in a large cohort of patients with nephrotic syndrome","volume":"32","author":"Gyamlani","year":"2017","journal-title":"Nephrol Dial Transplant."},{"key":"2026102121370782500_aajag121-B14","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1080\/0886022X.2022.2057861","article-title":"Anti-PLA2R antibody measured by ELISA predicts the risk of vein thrombosis in patients with primary membranous nephropathy","volume":"44","author":"Zhu","year":"2022","journal-title":"Ren Fail."},{"key":"2026102121370782500_aajag121-B15","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/ki.1989.310","article-title":"Multifactorial genesis of enhanced platelet aggregability in patients with nephrotic syndrome","volume":"36","author":"Machleidt","year":"1989","journal-title":"Kidney Int."},{"key":"2026102121370782500_aajag121-B16","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group","year":"2021","journal-title":"Kidney Int."},{"key":"2026102121370782500_aajag121-B17","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s40620-018-0552-9","article-title":"Recurrent venous thromboembolism in primary membranous nephropathy despite direct Xa inhibitor therapy","volume":"32","author":"Reynolds","year":"2019","journal-title":"J Nephrol."},{"key":"2026102121370782500_aajag121-B18","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med."},{"key":"2026102121370782500_aajag121-B19","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.amjmed.2021.11.018","article-title":"Risk of arterial thromboembolism, venous thromboembolism, and bleeding in patients with nephrotic syndrome: a population-based cohort study","volume":"135","author":"Vestergaard","year":"2022","journal-title":"Am J Med."}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/39\/7\/1411\/70650173\/aajag121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/39\/7\/1411\/70650173\/aajag121.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:37:12Z","timestamp":1792633032000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/39\/7\/1411\/8761579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":19,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,8,14]]},"published-print":{"date-parts":[[2026,10,22]]}},"URL":"https:\/\/doi.org\/10.1093\/joneph\/aajag121","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,14]]}}}